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Effective and safe delivery of the CRISPR/Cas9 gene-editing elements
remains a challenge. Here we report the development of PEGylated
nanoparticles (named P-HNPs) based on the cationic α-helical poly-
peptide poly(γ-4-((2-(piperidin-1-yl)ethyl)aminomethyl)benzyl-L-glu-
tamate) for the delivery of Cas9 expression plasmid and sgRNA to
various cell types and gene-editing scenarios. The cell-penetrating
α-helical polypeptide enhanced cellular uptake and promoted escape
of pCas9 and/or sgRNA from the endosome and transport into the
nucleus. The colloidally stable P-HNPs achieved a Cas9 transfection
efficiency up to 60% and sgRNA uptake efficiency of 67.4%, repre-
senting an improvement over existing polycation-based gene de-
livery systems. After performing single or multiplex gene editing
with an efficiency up to 47.3% in vitro, we demonstrated that P-
HNPs delivering Cas9 plasmid/sgRNA targeting the polo-like kinase
1 (Plk1) gene achieved 35% gene deletion in HeLa tumor tissue to
reduce the Plk1 protein level by 66.7%, thereby suppressing the
tumor growth by >71% and prolonging the animal survival rate
to 60% within 60 days. Capable of delivering Cas9 plasmids to
various cell types to achieve multiplex gene knock-out, gene
knock-in, and gene activation in vitro and in vivo, the P-HNP system
offers a versatile gene-editing platform for biological research and
therapeutic applications.
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cell-penetrating peptide
The clustered regularly interspaced short palindromic repeats,CRISPR-associated protein 9 (CRISPR/Cas9) system has
emerged as one of the most exciting tools for gene editing in re-
cent years (1). Compared with other systems that recognize target
sequences by programmable protein–DNA interactions (2), the
CRISPR/Cas9 system relies simply on base-pairing between the
single-guide RNA (sgRNA) and the target DNA. With a minimal
requirement in target design and straightforward construction of
sgRNAs, it facilitates widespread application in either funda-
mental research or therapeutic settings. However, effective de-
livery of active CRISPR/Cas9 remains a challenge (3).
Two critical components, Cas9 nuclease and sgRNA, are es-
sential for CRISPR/Cas9 activity. To enable effective gene editing,
the Cas9 and sgRNA expression cassettes are frequently encoded
within one plasmid for ease of codelivery. However, this approach
increases the plasmid size, which hinders effective transfection.
Moreover, in multiplexed genome editing, the cloning effort for
“all-in-one” vector construction can be burdensome and chal-
lenging for optimization, for example, in screening different
sgRNAs to realize multiplex gene editing after vector construc-
tion. Alternatively, the delivery of Cas9 expression plasmids and
sgRNAs could be separated with either sgRNA expression plas-
mids or in vitro-synthesized sgRNAs to provide flexibility.
Until now, most of the CRISPR/Cas9 delivery systems had re-
lied on physical or viral approaches. Physical methods, including
electroporation and microinjection, afford high transfection effi-
ciency but may suffer from low cell viability and cell-specific ef-
ficiency; physical methods are also difficult for in vivo application
(4, 5). Similarly, viral vectors achieve good performance on de-
livery of CRISPR/Cas9, but are limited by restricted packaging
capacity (6) or unwanted genetic mutations and immunogenicity
(7), posing concerns about safety in clinical translation. In compar-
ison, nonviral delivery methods via nanoparticles have the potential
to overcome many of these limitations, particularly with respect to
safety, large packaging capacity, and in vivo application (7).
Efficient delivery of Cas9 plasmids and synthesized sgRNAs by
nanoparticles requires proficient navigation through the extracel-
lular and intracellular barriers. Membrane-disruptive and endo-
somolytic materials are potent facilitators. Moreover, the timing of
intracellular release of Cas9 expression plasmids and sgRNAs is
also critical. And there is another consideration: nanocarriers
optimal for Cas9 expression plasmid delivery may not be suitable
for sgRNAs, as Cas9 expression plasmids are long double-stranded
DNA (9.3 kb) with high charge density while sgRNAs are 100-nt
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single-strand RNAs with lower charge density. Thus, nanocarriers
independently optimized for the delivery of Cas9 expression
plasmids and sgRNAs would be desirable.
Recently, cell-penetrating peptides (CPPs) (8), lipid-based nano-
particles (9–12), DNA nanoclews (13), gold nanoparticles (14, 15),
and “core-shell” artificial viruses (16) have been applied to Cas9/
gRNA delivery. The CPPs, based on materials for membrane de-
stabilization, such as HIV-TAT, GALA, and oligoarginine, have
been commonly incorporated into delivery vectors for membrane
destabilization to increase uptake, promote endosomal escape, and
improve overall transfection efficiency (17). We hypothesize that
using CPP alone as the delivery vector may be even more potent; a
single-component delivery vector is also advantageous for eventual
translation. However, for Cas9 expression plasmid delivery, the
conventional CPPs either are too small or lack an adequate cationic
charge density to function as stand-alone gene vectors. Additionally,
after complexing with the nucleic acids, the overall positive charge of
CPPs may be neutralized and the membrane-active domains of the
short oligopeptide would be partially shielded, thus reducing their
membrane activities as well as transfection efficiencies (17, 18). As
such, CPPs often play only a supportive role to improve the delivery
efficiencies of existing systems (17).
We previously reported the synthesis of water-soluble, α-helical
polypeptides bearing a cationic side-chain terminus (19) and
demonstrated the helicity-associated membrane activity that ren-
dered these polypeptides effective gene vectors (20, 21). This type
of helical polypeptide poly(γ-4-((2-(piperidin-1-yl)ethyl)amino-
methyl)benzyl-L-glutamate) (PPABLG) can bind and condense
both plasmid DNA and short siRNA while retaining the helical
structure to provide high membrane-penetrating ability for en-
hanced cellular internalization and endosomal escape. PPABLG
can also maintain stable helical structure against changes of envi-
ronmental conditions, such as pH, ionic strength, temperature, and
the presence of denaturing reagents (19), making it particularly
attractive for in vivo application. More importantly, PPABLG
features high stability against proteases, a distinct advantage over
the majority of CPPs that are prone to hydrolytic degradation
in vivo (20, 22). The desired enzymatic stability of PPABLG is
mainly due to its nonnatural amino acid sequences that cannot be
recognized by proteases and the long hydrophobic side chains that
hinder the access of proteases (19). Our previous data have also
shown that this kind of helical polypeptide has superior cell-
membrane permeability over HIV-TAT and Arg9 by up to two
orders of magnitude and thus affords excellent DNA and siRNA
delivery efficiencies in various mammalian cells (23, 24). After
complexing siRNA, the PPABLG could still maintain high mem-
brane activities (23, 24), a desired property that short oligopeptides
may not possess. PPABLG is a cationic polypeptide that could serve
the dual function of an efficient gene carrier and a cell-membrane–
penetrating agent. We thus hypothesized that the helical PPABLG,
with high positive charge, could complex Cas9 expression plasmids
and sgRNAs to form nano-complexes (referred to as helical
polypeptide nanoparticles, or HNPs). To enhance the extracellular
stability and the potential for in vivo application, the HNPs were
PEGylated (referred to as P-HNPs) through incorporation of
PEG-Polythymine40 (PEG-T40) in the formulation. We first eval-
uated this delivery system for multiplex gene editing in vitro (Fig.
1), followed by studying gene disruption in vivo.
Results and Discussion
PPABLG Synthesis and Nanoparticle Formulation. The cationic,
α-helical polypeptide PPABLG was synthesized and character-
ized via ring-opening polymerization of N-carboxyanhydride
monomers and subsequent side-chain functionalization through
ozonolysis and reductive amination (SI Appendix, Fig. S1) (20).
HNPs containing only the Cas9 expression plasmid (px165)
were formulated by adding the PPABLG solution into the plas-
mid solution at various weight ratios (PPABLG:px165 = 1:1–15:1).
The size of the polyplexes decreased from 230 nm to around
100 nm as the PPABLG/px165 ratio (wt/wt) increased from one to
five (SI Appendix, Fig. S2A), and the zeta potential increased from
1 to above 20 correspondingly. The polydispersity index (PDI)
value of HNPs at all PPABLG/px165 ratios was less than 0.2, in-
dicating relatively high uniformity.
Delivery of Cas9 Expression Plasmids into Various Primary and
Immortalized Cells. The plasmid that fuses the reporter gene
GFP to the Cas9 expression cassette [pSpCas9(BB)-2A-GFP and
abbreviated as px458] was used to facilitate the detection of
Cas9 expression in the transfected cells. As shown in SI Appendix,
Fig. S2B, HNPs formed by PPABLG:px458 (wt/wt = 30:1) dem-
onstrated the best transfection efficiency (∼48%) in HEK293T
cells, which was comparable to the transfection efficiency of the
pEGFP plasmid with dramatically smaller size (4.7 kb) (25).
However, such HNPs caused ∼30% cell death (SI Appendix, Fig.
S2C). Moreover, HNPs were colloidally unstable in serum-
containing medium (SI Appendix, Fig. S2D), which would com-
promise their in vivo performance. To address such an issue, we
next developed P-HNPs to decrease the cytotoxicity and enhance
the stability in serum (Fig. 1). Particularly, PEG-T40 was synthe-
sized and added to the plasmid solution at various weight ratios
before it was mixed with PPABLG. We varied the molecular
weight of PEG from 2 to 5 kDa, and the PEG-T40 content in
P-HNPs from 0.66% (PPABLG:px458:PEG-T40 = 30:1:0.2) to
3.22% (PPABLG:px458:PEG-T40 = 30:1:1). Addition of PEG-T40
did not change the size and zeta potential of the nanoparticles
compared with HNPs (SI Appendix, Fig. S3 A and B), and the
obtained P-HNPs with 3.22% PEG2k-T40 showed desired colloidal
stability in 10% FBS-containing medium, as evidenced by in-
appreciable alteration of the particle (SI Appendix, Fig. S2D). As
shown in SI Appendix, Fig. S3 C and D, P-HNPs modified with
PEG2k-T40 at the relative content of 3.22% showed the best GFP-
positive percentage and GFP mean fluorescence intensity compared
with polyethylenimine (PEI)/px458 treatment or HNPs treatment.
Cells treated by P-HNPs with PEG5k-T40 (1.61% PEG-T40 content)
also showed a high GFP-positive percentage, but were twofold lower
on the GFP mean fluorescence intensity compared with P-HNPs
modified with PEG2k-T40 at the relative content of 3.22%.
We also coated the PPABLG/px458 HNP complex with PEG2k-
T40 by adding PEG2k-T40 after forming the PPABLG/px458 HNPs
complex [named P-HNP(coating)]. P-HNP(coating) made at the
ratio of 30:1:1 (PPABLG:px458:PEG2k-T40) has a similar size
(87 nm) and zeta potential (20.8 mV) with P-HNPs made by mixing
the PEG2k-T40 with the plasmid before adding the PPABLG.
However, P-HNP(coating) reduced the transfection efficiency to 5%
Fig. 1. Schematic illustration showing the formation of P-HNPs and the
intracellular activity of Cas9 expression plasmid/sgRNA in performing ge-
nome editing or gene activation.
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(SI Appendix, Fig. S4), likely caused by the masking action of PEG-T40
in blocking the cellular penetration ability of PPABLG. For all
subsequent studies, we therefore settled on the formulation of
mixing PEG2k-T40 with the plasmid before adding PPABLG at
the ratio of 30:1:1 (PPABLG:px458:PEG2k-T40).
To evaluate the broad applicability of P-HNPs as Cas9 expres-
sion plasmid delivery vehicles, we performed plasmid transfection
experiments in a variety of cell types (Fig. 2). In cancer cell lines,
including HeLa and K562 cells, P-HNPs showed 32.9 and 11.0%
transfection efficiency, respectively. In other immortalized cell
lines, such as mouse fibroblast cells NIH 3T3 and dendritic cells
DC2.4, P-HNP transfection resulted in 55.0 and 14.7% of Cas9-
GFP expression, respectively. In primary cells of normal human
dermal fibroblasts (NHDF) and human umbilical cord blood-
derived endothelial progenitor cells (hEPCs), P-HNPs showed
24.6 and 27.7% transfection efficiency, respectively. P-HNPs for
px458 plasmid transfection in all these six cell lines yielded no
significant difference with HNP-based px458 plasmid transfection.
Compared with Lipofectamine 3000, the most potent commercially
available in vitro transfection reagent, P-HNPs performed better in
the K562 cells, DC2.4 cells, NHDF cells, and hEPCs. Noteworthy
is that P-HNPs lead to 1.9- to 4.9-fold higher transfection efficiency
than PEI/px458 treatment, which is the most commonly used
polycation gene transfection reagent (Fig. 2).
Cellular Internalization and Endosomal Escape of P-HNPs. To in-
vestigate the ability of P-HNPs to overcome cellular barriers, we
assessed the cellular uptake of P-HNPs by delivering YOYO-1–
labeled Cas9 expression plasmid px165. SI Appendix, Fig. S5A,
reveals that P-HNPs had a comparable cellular uptake level with
HNPs but outperformed PEI, which is consistent with the
px458 plasmid transfection results (SI Appendix, Fig. S3 C and
D). The cellular uptake for P-HNPs was inhibited by 36.1% at
4 °C, suggesting that most of the complexes enter the cell via
energy-independent nonendocytosis pathways (SI Appendix, Fig.
S5B). To investigate if the membrane permeability of PPABLG
was well-maintained after forming P-HNPs, we monitored the
cellular uptake of FITC–Tris, a hydrophilic membrane-imper-
meable fluorescent dye, in the presence of HNPs and P-HNPs
(20). As shown in SI Appendix, Fig. S5C, P-HNPs promoted
FITC–Tris uptake by ∼300-ng/mg protein as well as the HNP-
induced FITC–Tris uptake, suggesting that the PEGylation did
not abrogate the cell-membrane–penetrating ability of P-HNP.
The cellular uptake was also partially inhibited by chlorproma-
zine and wortmannin (SI Appendix, Fig. S5B), demonstrating that
the clathrin-mediated pathway and macropinocytosis were in-
volved in the endocytosis of P-HNPs. Additionally, the significant
inhibition by mβCD and genistein implied that the internalization
of P-HNPs was closely associated with caveolae-mediated uptake,
which is beneficial for plasmid release in the cytoplasm via the
bypass of lysosome formation and more direct translocation to
the Golgi or endoplasmic reticulum to facilitate nuclear transport
(26). Confocal laser scanning microscopy observation confirmed
the endosomal escape of the P-HNPs. As shown in SI Appendix,
Fig. S5D, in cells treated with P-HNPs as well as with HNPs,
YOYO-1–labeled px165 was distributed in the whole cytoplasm
and showed low colocalization with Lysotracker Red-stained
endosomes. The YOYO-1–labeled px165 was also localized to
the DAPI-stained nuclei in the HNP- and P-HNP–treated groups,
validating that Cas9 expression plasmids could be transferred
into cell nuclei to enable the Cas9 gene transcription (SI Appendix,
Fig. S5D).
Delivery of Cas9 Plasmids and sgRNAs for in Vitro Gene Disruption
and Endogenous Gene Editing.After establishing the efficiency of P-
HNPs in delivering Cas9 plasmids, we also confirmed their suit-
ability for delivering sgRNA (SI Appendix, Fig. S5E). The treat-
ment by P-HNPs (30:1:1) loaded with FITC-labeled sgRNAs
showed the best cellular uptake efficiency at 67.4% (SI Appendix,
Fig. S5E) and strongly outperformed PEI/sgRNA complexes
(9.8%) by sevenfold and Lipofectamine 3000 (33.5%) by twofold.
The U2OS.EGFP cell line, which constitutively expresses a
destabilized EGFP, was used as a model for the Cas9-induced
reporter gene disruption assay. P-HNPs codelivering two plas-
mids expressing Cas9 and EGFP-targeting sgRNAs at the ratio
of 2:1 (wt/wt for Cas9:sgRNA plasmids) produced the highest
EGFP absence efficiency (29.0%) and outperformed PEI/plas-
mid gene disruption efficiency (7.9%) (Fig. 3A). No reduction in
EGFP-positive cells was observed in control groups containing
naked plasmids or Cas9 plasmid alone.
EGFP deletion was also observed when the sgRNAs were de-
livered in the synthetic nucleic acid format by H-HNPs instead of
via transfection (SI Appendix, Fig. S6A). However, this only resulted
in a weakened EGFP gene disruption efficiency (19.2%). Similar
finding was reported by Miller et al. (27) when they used zwitter-
ionic amino lipid-based nanoparticles to deliver Cas9 expression
mRNAs and synthetic sgRNAs. We hypothesize that the presence
of Cas9 and sgRNA in the nuclei needs to be synchronized for
maximal gene editing. Observing a peak Cas9 protein at ∼24 h
posttransfection in our other experiments, we delivered the syn-
thetic sgRNAs 24 h after the Cas9 plasmid transfection and did
observe a higher EGFP disruption efficiency at 35.7% (Fig. 3 B and
C). The lower performance of the HNP group (24.9%) and the PEI
treatment group (8.2%) appeared to be related to the poorer cel-
lular uptake of the sgRNA nanoparticles (SI Appendix, Fig. S5E).
Fig. 2. Transfection of Cas9-GFP plasmid px458 in a
variety of cells. The HNPs were formed by PPABLG/
px458 at the wt/wt ratio of 30:1. The P-HNPs were
formed by PPABLG/px458/PEG2k-T40 at the wt/wt/wt
ratio of 30:1:1. Free, treatment with naked plasmids;
UT, untreated group.

















We also compared the EGFP disruption efficiency of P-HNPs with
the commercial formulations Lipofectamine 2000, Lipofectamine
3000, and Lipofectamine CRISPRMAX (SI Appendix, Fig. S6B).
Although the Lipofectamine CRISPRMAX could induce a higher
gene disruption (51.2%) compared with P-HNPs (36.5%), the de-
livery of Cas9 proteins may face concerns such as affordability,
purity of the Cas9 protein, and nonspecific nuclease action-medi-
ated toxicity, especially humoral immunity to Cas9 (28). In direct
comparison with Lipofectamine 2000 and 3000 in Cas9 plasmid and
sgRNA delivery, P-HNPs outperformed Lipofectamine 2000 and
were comparable to Lipofectamine 3000 in U2OS.EGFP cells. To
verify that the EGFP disruption arose from insertion-deletion
(indel) events, we applied the genomic cleavage detection (GCD)
assay to quantify the frequency of indels at the target EGFP locus
(Fig. 3D). We observed 39.7, 22.5, and 6.2% indels for the P-HNP,
HNP, and PEI treatment, respectively, which supported the results
of flow cytometry analysis (Fig. 3 B and C). The indel frequencies at
EGFP-target sites in cells treated by P-HNPs were also assayed
by DNA sequencing (SI Appendix, Fig. S6C). The sequencing of
21 clones showed 8 clones with mutations near the target site,
confirming that the gene disruption was mediated by the CRISPR/
Cas9 system. The EGFP disruption efficiency of the P-HNP delivery
system was comparable with the self-assembled DNANanoclews for
the Cas9 protein/sgRNA complex in the same cell line (13).
A major concern in using the CRISPR/Cas9 for genome en-
gineering is the off-target editing. Using the GCD assay to detect
the indels at two off-target sites for the EGFP-targeting sgRNA,
we observed a lower off-target cleavage (<2.8%) in cells treated
by sequentially delivering the Cas9 expression plasmid and the
synthetic sgRNAs (SI Appendix, Fig. S6D), compared with lipids
or short CPP-mediated Cas9 plasmid delivery if differences in
the targeted gene and sequence were neglected (8, 29).
After validating the reporter gene disruption in a model cell
line, we evaluated the genome editing of endogenous genes in
HEK293T cells. Noting the potential biomedical relevance of
editing the adeno-associated virus integration site 1 (AAVS1)
gene (30) and the hypoxanthine phosphoribosyltransferase 1
(HPRT1) gene (31), we evaluated the transfection of P-HNPs
loaded with Cas9 expression plasmids and sgRNA targeting
AAVS1 or HPRT1. The disruption efficiencies of 42.5% for the
AAVS1 gene or 46.0% for the HPRT1 gene (Fig. 3 E and F),
respectively, was higher than the published value using short CPP
(28% for the AAVS1 gene) (8), but lower than Lipofectamine 3000
(63% for the AAVS1 gene and 64% for the HPRT1 gene) (29).
We also explored the potential of multiplex gene editing based
on P-HNPs. We used P-HNPs to codeliver sgRNAs targeting
AAVS1 and HPRT1 at the weight ratio 1:1 at 24 h after cells
were treated by Cas9 expression plasmids, and detected the indels
formed at the AAVS1 and HPRT1 targeting site, respectively
(Fig. 3 E and F). It yielded 41.9% indels for the AAVS1 gene and
47.3% indels for the HPRT1 gene. Single delivery of sgRNAs
targeting AAVS1 or HPRT1 would not cause discernible off-target
editing to the other (Fig. 3 E and F), indicating the high specificity
for genome editing based on P-HNP delivery of CRISPR/Cas9.
Delivery of Cas9 Plasmids and sgRNA for in Vitro Gene Recombination.
CRISPR/Cas9 is a versatile editing tool not only for gene dis-









































Fig. 3. In vitro gene disruption. (A) EGFP disruption
assay of Cas9 expression plasmid and sgRNA expres-
sion plasmid delivery by HNPs or P-HNPs in U2OS.EGFP
reporter cells. The ratios in the figure are weight ra-
tios for Cas9 expression plasmid:sgRNA expression
plasmid. (B and C) EGFP disruption assay of Cas9 ex-
pression plasmid and in vitro-synthesized sgRNA de-
livery in U2OS.EGFP reporter cells. Short dash under
the bars in B indicates the group treated by only
Cas9 expression plasmids. (D–F) GCD assay of indels in
the EGFP gene in U2OS.EGFP cells (D), the AAVS1 gene
in HEK293T cells (E), and the HPRT1 gene in HEK293T
cells (F). “Multi” is the group treated by Cas9 expression
plasmid delivery and subsequent codelivery of AAVS1-
and HPRT1-targeting sgRNAs. Arrows indicate the cut-








Fig. 4. In vitro gene insertion and gene activation. (A) Donor architecture for
HDR of the AAVS1 gene. The arrows show the locations of PCR primers for
detecting successful HDR events. (B) PCR assay to detect HDR events 3 d after
transfection. (C) Microscopic images of two GFP+ clones after treatment by P-
HNPs loaded with Cas9 expression plasmids and the synthetic sgRNAs and HDR
donor after selection with puromycin for 2 wk. (Scale bar, 100 μm.) (D) Sanger
sequencing of the HDR events in the selected GFP+ clones in C. (E) The trans-
fection efficiency of P-HNPs for pMax-VP64dCas9-BFPVP64 plasmid by detecting the
BFP-positive cells. (F) The qRT-PCR evaluation of relative Myod1 mRNA level to
detect the Myod1 activation. The results were shown as the ratio relative to the
mRNA expression of the untreated cells. Free, treatment with naked nucleic acids;
UT, untreated group.
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offering an immense potential for biological and therapeutic ap-
plications. To investigate whether the P-HNP system could attain
gene insertion by homology-directed repair (HDR), we first de-
livered the Cas9 expression plasmid, followed by the delivery of
AAVS1 targeting sgRNA and the HDR donor template 24 h later
using the same P-HNP carrier (Fig. 4A). The GFP and puromycin
expression sequences were involved in the HDR donor template.
Three days after transfection, the HDR events were verified by
PCR using a forward primer recognizing the AAVS1 genome and
a reverse primer binding to the puromycin gene in the donor
template (Fig. 4A and SI Appendix, Table S1). PCR assay dem-
onstrated that only cells treated with the delivery of Cas9 ex-
pression plasmids, sgRNAs, and HDR donor templates exhibited
HDR events (Fig. 4B). Cells treated with nanoparticles delivering
sgRNA and donor only, without Cas9 expression plasmid, did not
show any PCR product. This result demonstrated that the in-
creased HDR events were initiated by CRISPR/Cas9 cleavage,
not by traditional HDR events. Although both the transfection of
PEI complexes and HNPs showed HDR events, the PCR prod-
ucts of P-HNP transfection were more intense. Several clones
with strong GFP expression were formed after selection with
puromycin for 2 wk (Fig. 4C). The HDR event was also con-
firmed by Sanger sequencing of the selected clone’s genome and
detection of the expected DNA bases at the genome-donor
boundary (Fig. 4D).
Delivery of dCas9 Plasmids and sgRNA for in Vitro Gene Activation.
The CRISPR/Cas9 technology can also be applied to activate
gene expression by introduction of point mutations into the
Cas9 nuclease domain to generate a deactivated Cas9 (dCas9)
and then by fusing a transactivator such as VP64 to dCas9 (32,
33). We tested the delivery efficiency of the pMax-VP64dCas9-
BFPVP64 plasmid of PEI, HNP, and P-HNP. The design of
pMax-VP64dCas9-BFPVP64 is such that the dCas9 is fused to two
transactivation VP64 domains for higher activation and a BFP
protein for ease of detection and optimization (32, 33). P-HNP
transfection on NIH 3T3 cells resulted in 41.5% BFP expression,
with no significant difference compared with HNP transfection
but 2.6-fold higher than PEI transfection (Fig. 4E). This is con-
sistent with the data for the px458 plasmid transfection on NIH
3T3 cells. We next targeted the Myod1 gene, a critical factor
that, when activated, can induce the reprogramming of mouse
embryonic fibroblasts to skeletal myocytes (33). By delivery of
pMax-VP64dCas9-BFPVP64 plasmids and Myod1-targeted sgRNA,
P-HNPs efficiently increased the Myod1 mRNA level 5.4-fold
after a single transfection and 8.4-fold after three sequential
transfections (Fig. 4F). After three sequential transfections, P-
HNPs showed a twofold higher level of Myod1 activation com-
pared with PEI-based transfection.
Delivery of Cas9 Plasmids and sgRNA for in Vivo Gene Disruption and
Tumor Growth Suppression. There is often a disconnect between
the in vitro and in vivo performance of nanomedicines. To eval-
uate if the promising P-HNP delivery system is also applicable for
gene editing in vivo, we tested the in-tumor gene-editing feasibility
of P-HNPs in A549.GFP tumor-bearing mice. Two days after the
last injection, many A549.GFP cells near the injection site showed
loss or decrease of GFP fluorescence (SI Appendix, Fig. S7A). In
contrast, the tumors in the PBS-treated mice or in the mice
treated with P-HNPs delivering Cas9 expression plasmids alone
did not show any loss of GFP signal. The GFP gene disruption was
confirmed by indel detection at the target gene site in the lysed
tumor tissue (SI Appendix, Fig. S7B). Treatment by P-HNPs
loaded with Cas9 expression plasmids and with synthesized GFP
targeting sgRNAs caused 29.7% of the indels at the target site.
After validating the capability of P-HNPs in reporter GFP
gene disruption in tumors, we further investigated the gene
editing of the survival gene, polo-like kinase 1 (Plk1), for anti-
cancer therapy. Plk1 is a highly conserved serine–threonine ki-
nase that promotes cell division, and overexpression of Plk1 is
found in various tumors (34). Inhibition or depletion of Plk1
expression leads to cell-cycle arrest, apoptosis, and “mitotic ca-
tastrophe” in cancer cells, which provides a promising modality
for anticancer therapy. Delivery of Cas9 expression plasmids and
synthesized Plk1-targeting sgRNAs (denoted as P-HNPPCas9+sgPlk1)
to HeLa cells caused obvious indels at the target site in HeLa
cells in vitro (Fig. 5A). In comparison, P-HNPs encapsulating
only the Cas9 expression plasmid (denoted as P-HNPPCas9)
showed no cleavage of Plk1. As a result of Cas9/sgRNA-mediated
Plk1 disruption, the P-HNPPCas9+sgPlk1 inhibited the proliferation
of HeLa cells by 43.2% and caused cell apoptosis by 46.2%, which
was significantly higher than P-HNPPCas9 (Fig. 5B and SI Appendix,
Fig. S7C). Next, we evaluated the tumor inhibition efficacy of P-
HNPs in HeLa xenograft tumor-bearing mice. P-HNPPCas9+sgPlk1
C D
A EB
Fig. 5. In vivo gene disruption and tumor growth
suppression. (A) Indels of the Plk1 gene in HeLa cells
treated with P-HNPs containing px165 only (P-HNPPCas9)
or P-HNPs containing px165 and Plk1-targeting sgRNAs
(P-HNPPCas9+sgPlk1). (B) Viability of HeLa cells at 72 h af-
ter transfection with P-HNPPCas9 or P-HNPPCas9+sgPlk1.
Free, cells treated with free px165 and free Plk1-tar-
geting sgRNAs; UT, untreated cells. (C) The inhibition
of tumor growth in HeLa xenograft tumor-bearing
mice after intratumoral injection of P-HNPPCas9 or
P-HNPPCas9+sgPlk1 (n = 7). Black and red arrows indicate
the injection day of P-HNPPCas9 or P-HNPs containing
Plk1-targeting sgRNAs (P-HNPsgPlk1), respectively. The
injection dose was 20 μg for PCas9 or sgPlk1. (D) Sur-
vival of HeLa xenograft mice in C. Euthanasia was
performed when tumor volumes reached 1,000 mm3.
(E) Expression level of Plk1 protein in tumor tissues in C,
analyzed at 48 h post last injection.

















achieved significant tumor inhibition in comparison with PBS, free
Cas9 plasmid/free sgPlk1, and P-HNPPCas9, leading to a tumor
suppression of >71% (Fig. 5C). Accordingly, P-HNPPCas9+sgPlk1
notably improved the survival rate of mice to 60% (Fig. 5D). The
body weight of mice did not change noticeably compared with the
control group, suggesting low toxicity of P-HNPs (SI Appendix, Fig.
S7D). In consistence with the antitumor efficacy, P-HNPPCas9+sgPlk1
led to remarkable cancer cell necrosis in hematoxylin and eosin
(H&E)-stained tumor tissues and afforded the highest cell re-
mission level in tumor tissue sections immune-stained with EdU-
594 (SI Appendix, Fig. S7E). To further confirm the CRISPR/
Cas9-mediated in vivo gene editing of Plk1, the indel frequency
at the Plk1 locus in tumor tissues following P-HNPPCas9+sgPlk1
treatment was measured by deep sequencing. Among the se-
quenced 20 clones, 7 clones had mutations near the target site,
including two single nucleic acid insertions, one G→A single nucleic
acid mutation, and four large deletions (SI Appendix, Fig. S8). The
final genome-editing efficiency in the Plk1 locus mediated by P-
HNPPCas9+sgPlk1 was calculated to be 35%. Western blot analysis
further confirmed that the manipulation in the Plk1 genome caused
a 67% decrease of the Plk1 protein expression level (Fig. 5E),
supporting the finding that P-HNPPCas9+sgPlk1 inhibited the tumor
growth by depletion of the Plk1 gene in tumor tissues. While these
results suggest the applicability of P-HNPs for local in vivo
CRISPR/Cas9 gene editing toward anticancer therapy, its potential
for systemic application remains a subject of ongoing investigation.
Work is in progress to modify the synthesized sgRNAs for higher
stability, to understand the biodistribution via different adminis-
tration routes, and to evaluate the targeting ability of this delivery
system for various gene-editing applications in vivo.
Conclusions. In this work, we reported the synthesis and applica-
tion of a PEGylated nanoparticle, P-HNP, based on the cationic
α-helical polypeptide PPABLG and Cas9 expression plasmids/
sgRNAs for genome editing in mammalian cells and in tumor
tissue. The P-HNPs showed high membrane-penetrating ability to
facilitate cell uptake, escape from the endosome, and translocate
into the nucleus for CRISPR/Cas9-based genome editing. The P-
HNPs efficiently delivered Cas9 plasmid or sgRNA, as a complex
or separately, to various cell types including tumor cells, fibro-
blasts, dendritic cells, and human endothelial progenitor cells to
achieve multiplex gene knockout, demonstrating an advantage
over the existing polycation-based gene vectors. P-HNPs could
also mediate gene knock-in and gene activation. In vivo studies
further indicated the efficiency of this nonviral gene-editing sys-
tem for topical anticancer therapy. Given the potency of PPABLG
for systemic siRNA delivery in vivo, this work suggests the broad
potential of P-HNPs for nonviral gene editing.
Materials and Methods
Detailed materials and methods are provided in SI Appendix, including the
synthesis of PPABLG and PEG-T40, preparation and characterization of HNPs
and P-HNPs, and delivery of plasmids and sgRNAs in vitro and in vivo.
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